PT  - JOURNAL ARTICLE
AU  - Meng Zhang
AU  - Gerard A. Bouland
AU  - Henne Holstege
AU  - Marcel J.T. Reinders
TI  - Identifying aging and Alzheimer’s disease associated somatic mutations in excitatory neurons from the human frontal cortex using whole genome sequencing and single cell RNA sequencing data
AID  - 10.1101/2022.05.25.22275538
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.25.22275538
4099  - http://medrxiv.org/content/early/2022/05/26/2022.05.25.22275538.short
4100  - http://medrxiv.org/content/early/2022/05/26/2022.05.25.22275538.full
AB  - With age, somatic mutations accumulated in human brain cells can lead to various neurological disorders and brain tumors. Since the incidence rate of Alzheimer’s disease (AD) increases exponentially with age, investigating the association between AD and the accumulation of somatic mutation can help understand the etiology of AD. Here we built a somatic mutation detection pipeline by contrasting genotypes derived from WGS data with genotypes derived from scRNA-seq data and applied this pipeline to 76 participants from the ROSMAP project. We focused only on excitatory neurons, the dominant cell type in the human brain. As a result, we identified 196 sites that harbored at least one individual with an excitatory neuron-specific somatic mutation (ENSM) across all individuals, and these 196 sites were mapped to 127 genes. The single base substitution (SBS) pattern of the putative ENSMs was best explained by signature SBS5 from the COSMIC mutational signatures, a clock-like pattern correlating with the age of the individual. The count of ENSMs per individual also showed an increasing trend with age. Among the mutated sites, we found two sites to have significantly more mutations in older individuals (16:6899517 (RBFOX1), p = 0.044; 4:21788463 (KCNIP4), p = 0.045). Also, two sites were found to have a higher odds ratio to detect a somatic mutation in AD samples (6:73374221 (KCNQ5), p = 0.014 and 13:36667102 (DCLK1), p = 0.023). 32 genes that harbor somatic mutations unique to AD and the KCNQ5 and DCLK1 genes were used for GO-term enrichment analysis. We found the AD-specific ENSMs enriched in the GO-term “vocalization behavior” and “intraspecies interaction between organisms”. Interestingly, we observed both age- and AD-specific ENSMs enriched in the K+ channels-associated genes. Taken together this shows our pipeline that combines scRNA-seq and WGS data can successfully detect putative somatic mutations. Moreover, the application of our pipeline to the ROSMAP dataset has provided new insights into the association of AD and aging with brain somatic mutagenesis.Author summary Somatic mutations are changes in the DNA that occur during life. As with increasing age, somatic mutations also accumulate in human brain cells and can potentially lead to neurological diseases such as Alzheimer’s disease (AD). Associating the occurrence of somatic mutations in human brains with increasing age as well as AD can provide new insights into the mechanisms of aging and the etiology of AD. But somatic mutations do not accumulate similarly across different cell types. Single cell RNA sequencing provides an opportunity to derive somatic mutations for different cell types. We describe a methodology to detect cell-type specific somatic mutations and demonstrate the effectiveness of this methodology by applying it to human brain single cell data of 76 participants from the ROSMAP project. The detected somatic mutational pattern resembles a known clock-like mutational signature, and the number of somatic mutations per person also increases with age. We also identify specific sites that have a higher incidence rate of somatic mutations in AD or associated with increasing age. We further use these findings to postulate molecular pathways enriched with somatic mutations in AD people contributing to the etiology of AD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by an NWO Gravitation project: BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology (NWO: 024.004.012).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Rush University Medical Center gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are partly available upon reasonable request to the authors.